USA PwC’s Kelly Barnes examines how the US pharmaceutical sector is having to rethink its relationship with consumers, experimenting with new and innovative pricing models, and adopting a more holistic view of the patients using their medicines.   American consumers want more than just lower prices from pharmaceutical companies US Consumers…

Vaccines MSD’s Cyril Schiever outlines why vaccine hesitancy is such a threat to global health, the misinformation around vaccines being spread online, and how multi-stakeholder collaboration can help counter this emerging problem.   The World Health Organization (WHO) recently identified vaccine hesitancy as one of the top 10 global health threats…

Brazil Rodrigo Araujo of global organizational consulting firm Korn Ferry outlines what he sees as the leadership profile of the future – agile, digital, self-aware, and able to transform both themselves and their organizations.   What are the qualities you look for in a Country Manager? Capable leaders are those who…

USA Eurasia Group’s Aditya Bhattacharji looks at the potentially damaging fallout of the ongoing US-China trade war on the life sciences industry.   Biotech [is the] new frontier for US-China tensions The G20 gathering in Osaka at the end of June was, overall, less tense than other multilateral fora over the…

Puerto Rico Puerto Rico’s close-knit pharmaceutical sector is aiming to attract new talent to the industry so as to further increase its global competitiveness.   There is a strong, robust ecosystem around the pharmaceutical industry on the island and we are looking to attract the new generation to work in it Wendy…

Egypt Egypt has seen a decade of great transformation, from political instability and uncertainty to its current relative stability. Healthcare reform now stands near the top of the government’s agenda and efforts are being made to roll out universal healthcare and provide greater access to affordable treatments to the entire population. …

Opinion Ulrich Neumann of Certara outlines recent developments in the use of real-world evidence (RWE) and the sizeable impact it stands to make on the global biopharma industry.   While the collection of real-world data is not new, real-world evidence is poised to have a profound impact on the biopharma industry…

Thailand PharmaBoardroom last reported on Thailand in 2015, meeting country managers from across the healthcare and life sciences value chain. Here, we chart some of their career progressions since then.   Sticking with Servier Guillaume Drianno Guillaume Drianno was Thailand country manager for French firm Servier between 2013 and 2017. Prior…

Biotech With a strong research base formed around the Karolinska Institute and Uppsala University, Sweden has grown to be one of Europe’s premier biotech hotspots. Several companies spun out of research conducted at these institutes and others are now listed on the Stockholm stock exchange and already have products on the…

USA Chip Davis of the Association for Accessible Medicines argues that learning from the European biosimilars approval experience could speed up patient access to these complex drugs in the USA.   Advancements in biologic research and development have brought forth life-saving treatments for patients with cancer as well as such chronic…

Opinion David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in the cell and gene therapy market for investments and deal activities.   Background Cell and gene therapies hold the promise of bringing significant clinical benefits to patients by directly targeting the underlying cause of disease. With tremendous…

Janssen PharmaBoardroom recently sat down with Janssen EMEA head Kris Sterkens, who outlined the enduring importance of Europe to the global group, even with the emergence of Asian power markets such as China and the continuing significance of the USA. Read the full interview here.   Where Europe really does excel…